Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Geoffrey A. Head, Baker Heart and Diabetes Institute, Australia

*CORRESPONDENCE Dariusz Szukiewicz, dariusz.szukiewicz@wum.edu.pl

SPECIALTY SECTION This article was submitted to Exercise Physiology, a section of the journal Frontiers in Physiology

RECEIVED 20 September 2022 ACCEPTED 03 October 2022 PUBLISHED 17 October 2022

CITATION

Szukiewicz D and Eubanks JH (2022), Editorial: Sirtuins and brain homeostasis. *Front. Physiol.* 13:1049226. doi: 10.3389/fphys.2022.1049226

COPYRIGHT

© 2022 Szukiewicz and Eubanks. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Sirtuins and brain homeostasis

Dariusz Szukiewicz¹* and James Howard Eubanks²

¹Department of Biophysics, Physiology and Pathophysiology, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland, ²Division of Experimental and Translational Neuroscience, Krembil Research Institute, University Health Network, Toronto, ON, Canada

KEYWORDS

brain homeostasis, neurodegenerative disease, neuroprotection, neuroinflammation, sirtuins

Editorial on the Research Topic Sirtuins and brain homeostasis

The homeostatic functions of the human brain include but are not limited to maintaining daily physiological cycles, such as the sleep-wake cycle, controlling appetiteand thirst, regulating energy and glucose metabolism, regulating body temperature and blood pressure, controlling the production and release of hormones, and regulating cognitive processes (Grigorenko et al., 2016; Roh et al., 2016; González-García et al., 2021). Therefore, the preservation of brain homeostasisis crucial for maintaining the state of steady internal, physical, and chemical conditions of a whole organism (Graceli et al., 2020). Epigenetic mechanisms that control gene expression/ activity without changing the DNA sequence play an important role in brain homeostasis. These mechanisms include DNA methylation, histone modifications, nucleosome repositioning, higher-order chromatin remodeling, noncoding RNAs, and RNA and DNA editing (Mehler, 2008; Mansuy and Mohanna, 2011; Petralla et al., 2021). Sirtuins comprise a family of evolutionarily conserved enzymes that perform NAD⁺-dependent protein deacetylation/acetylation and are involved in the epigenetic machinery (Bosch-Presegué and Vaquero, 2015; Kosciuk et al., 2019). In mammals, seven isoforms of sirtuins (SIRT1-SIRT7) have been identified in different cellular compartments (i.e., nucleus, mitochondria, cytosol), and knowledge about their comprehensive operation is rapidly expanding (Grabowska et al., 2017; Avilkina et al., 2022).

This special issue, consisting of original and review papers, has been prepared to showcase thelatest information about the role of sirtuins in the preservation of brain homeostasis in neurological disorders, including neurodegenerative diseases and stroke, and in the context of behavioral responsiveness.

A literature review clearly shows that sirtuins regulate various cell functions in the central nervous system (CNS) (Yan et al.). In the mature CNS, this applies to both neurons and glial cells (i.e., astrocytes, oligodendrocytes, and microglial cells). Abnormal levels of sirtuins coexist with CNS disorders, resulting in clinically relevant progressive cognitive impairment and dysfunction of social and physical abilities. Thus, as epigenetic factors, sirtuins participate in processes such as oxidative stress, cell mitigation, apoptosis, and mitochondrial biogenesis, and altered sirtuin



SIRT3 counteracts oxidative stress through FoxO3A deacetylation, resulting in MnSOD activation and/or direct MnSOD activation via deacetylation. Thus limited formation of ROS inhibits NLRP3 activation. SIRT2 may inhibit NLRP3 through deacetylation of α -tubulin. SIRT1 facilitates A β degradation by upregulating lysosome number (Li et al., 2018). * TLRs are one example of a group of receptors that may be replaced with SRs or RAGE \ddagger SIRT2 actions seem to be more complex because on some research models, its inhibition abrogates neuroinflammation more effectively than its activation A β aggregates, aggregates of amyloid-beta; Ac, acetylation; DAc, deacetylation; DNMT1, DNA Methyltransferase 1; FoxO3A, the transcription factor Forkhead box protein O3a; IKK α , Inhibitor of nuclear factor kappa-B kinase subunit alpha; IKK β , Inhibitor of nuclear factor kappa-B kinase subunit alpha; IKK β , Inhibitor of nuclear factor kappa-B kinase subunit alpha; IKK β , Inhibitor of nuclear factor kappa-B kinase subunit alpha; IKK β , Inhibitor of nuclear factor kappa-B kinase subunit alpha; IKK β , Inhibitor of nuclear factor kappa-B kinase subunit alpha; IKK β , Inhibitor of nuclear factor kappa-B kinase subunit gamma (IKK- γ); NF- $\kappa\beta$, nuclear factor kappa-Ightpessential modulator NEMO also known as inhibitor of nuclear factor kappa-B kinase subunit gamma (IKK- γ); NF- $\kappa\beta$, nuclear factor kappa-Ightchain-enhancer of activated β cells; P, phosphorylation; p50, subunit p50 of the NF-kappaB p50/p65 heterodimer; p65, subunit p65 of the NFkappaB p50/p65 heterodimer; ROS, reactive oxygen species; SIRT1, 2, 3, sirtuins: 1, 2, and 3; TLRs, Toll-like receptors; Ub, ubiquitination.

production may be a manifestation of compensatory mechanisms rather than their involvement in the pathomechanism. Apart from a few exceptions, the neuroprotective effect in CNS cells is attributed to sirtuins. It may even be assumed that, acting simultaneously, SIRT1-SIRT7 proteins synergistically enhance brain homeostasis via distinct cellular regulatory pathways. The latest achievements in research on the role of sirtuins in cognitive functioning are reviewed in a separate paper (Fagerli et al.). Naturally, cognitive function, including memory, attention, decision-making, perception, and language comprehension, is important in daily life at any age (Gonzales et al., 2022). Cognitive deficits often appear in individual life following cerebral ischemia due to stroke or cardiac arrest, and this predisposes an individual to dementia. A rationale for the therapeutic potential of targeting sirtuins to ameliorate cognitive deficits in neurological disorders is based on the welldocumented contribution of sirtuins in the epigenetic regulation of synaptic protein expression and dendritic density. Thus, an indepth study of the role of sirtuins in the modulation of synaptic plasticity under basal conditions as well as pathological states may be promising with respect to the development of novel treatments for neurodegenerative diseases (Gupta et al., 2022). In addition, sirtuins can inhibit some processes that underlie the molecular pathology of Alzheimer's disease (e.g., neuroinflammation, neuroinflammation-related oxidative stress, amyloid beta (AB)protein aggregate deposition, and neurofibrillary tangle formation); thus, they can prevent many of those pathologic alterations at relatively early stages of their development (Watroba and Szukiewicz). The anti-neuroinflammatory actions of sirtuins manifest mainly through the inactivation of the p65 subunit of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB), the activation of DNA methyltransferase 1 (DNMT1), and antioxidative effects (Figure 1).

However, it should be noted that the neuroprotective effects of proteins may not be revealed in certain situations. It was demonstrated that SIRT1 and SIRT2 are involved in the response of brain cells to ischemia in the first 24 h after photothrombotic stroke, but the alterations in their expression and change in the localization of SIRT1 were not linked to the regulation of apoptosis within the viable tissue around the irreversibly damaged ischemic core (penumbra cells) (Eid et al.). However, the lack of influence on the intensity of apoptosis does not exclude the other beneficial actions of sirtuins in the ischemic brain. In addition, the limitations of the model of photothrombosis used make it suitable for the study of the molecular mechanisms of ischemic damage, rather than the mechanisms of ischemiareperfusion damage to the cells, indicate that the neuroprotective action of sirtuins may be important (Conti et al., 2017; Afzaal et al., 2022).

A study on SIRT3-knockout (KO) mice revealed that mitochondrial brain proteome acetylation levels may influence behavioral responsiveness (Sidorova-Darmos et al.). Disturbance of brain homeostasis due to a lack of the primary protein deacetylase enzyme in mitochondria, SIRT3, caused increased acetylation and altered mitochondrial function. Both male and female SIRT3-KO mice displayed hyperlocomotion and attenuated anxiety-like behavior in response to a dose of amphetamine.

Given the pivotal functions of sirtuins as epigenetic factors that regulate brain homeostasis, the therapeutic potential of sirtuin modulators, both inhibitors and activators, should be considered in the context of CNS disorders (Fiorentino et al., 2022).

References

Afzaal, A., Rehman, K., Kamal, S., and Akash, M. S. H. (2022). Versatile role of sirtuins in metabolic disorders: From modulation of mitochondrial function to therapeutic interventions. *J. Biochem. Mol. Toxicol.* 36 (7), e23047. doi:10.1002/jbt.23047

Avilkina, V., Chauveau, C., and GhaliMhenni, O. (2022). Sirtuin function and metabolism: Role in pancreas, liver, and adipose tissue and their crosstalk impacting bone homeostasis. *Bone* 54, 116232. doi:10.1016/j.bone.2021.116232

Bosch-Presegué, L., and Vaquero, A. (2015). Sirtuin-dependent epigenetic regulation in the maintenance of genome integrity. *FEBS J.* 282 (9), 1745–1767. doi:10.1111/febs.13053

Conti, V., Forte, M., Corbi, G., Russomanno, G., Formisano, L., Landolfi, A., et al. (2017). Sirtuins: Possible clinical implications in cardio and cerebrovascular diseases. *Curr. Drug Targets* 18 (4), 473–484. doi:10.2174/1389450116666151019095903

Fiorentino, F., Mautone, N., Menna, M., D'Acunzo, F., Mai, A., and Rotili, D. (2022). Sirtuin modulators: Past, present, and future perspectives. *Future Med. Chem.* 14 (12), 915–939. doi:10.4155/fmc-2022-0031

Gonzales, M. M., Garbarino, V. R., Pollet, E., Palavicini, J. P., Kellogg, D. L., Jr, Kraig, E., et al. (2022). Biological aging processes underlying cognitive decline and neurodegenerative disease. J. Clin. 132 (10), e158453. doi:10.1172/JCI158453

González-García, I., Gruber, T., and García-Cáceres, C. (2021). Insulin action on astrocytes: From energy homeostasis to behaviour. *J. Neuroendocrinol.* 33 (4), e12953. doi:10.1111/jne.12953

Grabowska, W., Sikora, E., and Bielak-Zmijewska, A. (2017). Sirtuins, a promising target in slowing down the ageing process. *Biogerontology* 8 (4), 447–476. doi:10.1007/s10522-017-9685-9

Graceli, J. B., Dettogni, R. S., Merlo, E., Niño, O., da Costa, C. S., Zanol, J. F., et al. (2020). The impact of endocrine-disrupting chemical exposure in the mammalian

Author contributions

As the Topic Editors, both DS and JE performed similar tasks with similar commitment and contributed to the selection of submitted manuscripts, were involved in recruiting the reviewers and participated in making the final decision about the manuscripts after the peer-review process was completed. Notwithstanding the above, DS was the co-author of the review paper and JS was the co-author of the original research paper published in this special issue.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

hypothalamic-pituitary axis. Mol. Cell. Endocrinol. 518, 110997. doi:10.1016/j.mce. 2020.110997

Grigorenko, E. L., Kornilov, S. A., and Naumova, O. Y. (2016). Epigenetic regulation of cognition: A circumscribed review of the field. *Dev. Psychopathol.* 28 (4), 1285–1304. doi:10.1017/S0954579416000857

Gupta, R., Ambasta, R. K., and Kumar, P. (2022). Multifaced role of protein deacetylase sirtuins in neurodegenerative disease. *Neurosci. Biobehav. Rev.* 132, 976–997. doi:10.1016/j.neubiorev.2021.10.047

Kosciuk, T., Wang, M., Hong, J. Y., and Lin, H. (2019). Updates on the epigenetic roles of sirtuins. *Curr. Opin. Chem. Biol.* 51, 18–29. doi:10.1016/j.cbpa.2019.01.023

Li, M. Z., Zheng, L. J., Shen, J., Li, X. Y., Zhang, Q., Bai, X., et al. (2018). SIRT1 facilitates amyloid beta peptide degradation by upregulating lysosome number in primary astrocytes. *Neural Regen. Res.* 13 (11), 2005–2013. doi:10. 4103/1673-5374.239449

Mansuy, I. M., and Mohanna, S. (2011). Epigenetics and the human brain: Where nurture meets nature. *Cerebrum*. 2011, 8.

Mehler, M. F. (2008). Epigenetic principles and mechanisms underlying nervous system functions in health and disease. *Prog. Neurobiol.* 86 (4), 305–341. doi:10. 1016/j.pneurobio.2008.10.001

Petralla, S., De Chirico, F., Miti, A., Tartagni, O., Massenzio, F., Poeta, E., et al. (2021). Epigenetics and communication mechanisms in microglia activation with a view on technological approaches. *Biomolecules* 11 (2), 306. doi:10.3390/biom11020306

Roh, E., Song, D. K., and Kim, M. S. (2016). Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism. *Exp. Mol. Med.* 48 (3), e216. doi:10.1038/emm.2016.4